Elliot Marseille, DrPH, MPP, is a health economist whose work sits at the intersection of psychedelic science, public health, and policy. He directs the Collaborative for the Economics of Psychedelics at UC Berkeley, where he and collaborators develop rigorous, decision-relevant analyses of psychedelic-assisted therapies—spanning cost-effectiveness, access, pricing, and implementation. The work of CEP is designed to inform payers, regulators, and health systems on coverage and scale-up. Recent projects and publications examine the cost-effectiveness and epidemic impact of MDMA-assisted therapy for PTSD, psilocybin for depression, the pricing of MDMA, the feasibility of introducing psychedelic therapies to low- and middle-income countries, the economics and epidemic impact of making ibogaine-assisted therapy available for people with opioid use disorder, and the system-level efficiencies possible with group-based delivery models. Partners have included federal agencies, leading academic centers, and nonprofits. Marseille’s career is grounded in three decades of HIV/AIDS and global health economics. He has led and advised studies for the CDC, the World Bank, the Bill & Melinda Gates Foundation, and ministries of health across Africa and Asia, contributing evidence on a wide range of global health interventions. With over 40 years of senior public health research experience, Dr. Marseille has published more than 80 peer-reviewed articles. Across these domains, Marseille’s work emphasizes transparent methods, policy realism, and practical pathways to equitable access—bringing the same quantitative discipline to psychedelic therapies that he has long applied to HIV and other global health priorities.